Senior Clinical Researcher, University of Oxford
Director, Oxford Brain Health Clinical Trials Unit
Deputy Theme Lead: Older adults and dementia
My clinical and research interests are in the late life cognitive effects of traumatic brain injury (TBI) and memory disorders and dementia, as well as clinical trials in cognitive impairment. I have worked for over 20 years in clinical trials in the UK and US and was previously lead clinician on a US NIH-based study of Vietnam veterans with head injuries. Most of my research is around exploring validated and novel biomarkers in order to develop marker sets for identification, tracking and measuring outcome of early neurodegenerative disease and how these may interact with risk factors such as head injury earlier in life. I am part of the steering group for the Oxford Brain Health Centre and am involved with a number of new service developments around managing risks for dementia and early cognitive impairment.
I am currently the Principal Investigator for the New Therapeutics in Alzheimer’s Disease (NTAD), Brains for Dementia Research (BDR) and 7Tesla MRI Scanning in Alzheimer’s disease and Frontotemporal Lobar Degeneration studies and Chief Investigator on the Deep and Frequent Phenotyping (DFP) and MIcroglial CSF1R in Alzheimer’s Disease (MICAD) studies. I am the Director of the Oxford Brain Health Clinical Trials Unit, Associate Director for Dementias Platform UK2 (lead for Trial Delivery Framework) and Dementia and NIHR Dementia and Mental Health Lead for the Thames Valley and South Midlands Clinical Research Network.
View Vanessa Raymont’s profile on the Department of Psychiatry website.